iSpecimen Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
iSpecimen Inc. (ISPC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.16 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-05-19
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $1.16K, a 97.48% decline year-over-year.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $20.30K, a 58.90% decline year-over-year.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $34.83K, a 16.78% increase year-over-year.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $45.87K, a 16.00% decline year-over-year.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $101.84K, a 36.35% decline from fiscal 2023.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $160.01K, a 75.08% decline from fiscal 2022.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $642.08K, a 3.22% increase from fiscal 2021.
- iSpecimen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $622.06K, a 569.85% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $1.16K 10-Q · filed 2025-05-19 | ||||
| 2024-12-31 | $101.84K 10-K · filed 2025-04-14 | ||||
| 2024-09-30 | $20.30K 10-Q · filed 2024-11-07 | $55.14K derived: sum of 2 quarters · filed 2024-11-07 | $101.01K derived: sum of 3 quarters · filed 2025-05-19 | ||
| 2024-06-30 | $34.83K 10-Q · filed 2024-11-07 | $80.70K derived: sum of 2 quarters · filed 2025-05-19 | |||
| 2024-03-31 | $45.87K 10-Q · filed 2025-05-19 | ||||
| 2023-12-31 | $160.01K 10-K · filed 2025-04-14 | ||||
| 2023-09-30 | $49.39K 10-Q · filed 2024-11-07 | $79.22K derived: sum of 2 quarters · filed 2024-11-07 | $133.83K derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $29.83K 10-Q · filed 2024-11-07 | $84.44K derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $54.61K 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $642.08K 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $183.27K 10-Q · filed 2023-11-02 | $385.59K derived: sum of 2 quarters · filed 2023-11-02 | $569.00K derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $202.32K 10-Q · filed 2023-11-02 | $385.73K derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $183.41K 10-Q · filed 2023-11-02 | $184.19K 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $622.06K 10-K/A · filed 2023-03-30 | ||||
| 2021-09-30 | $399.82K 10-Q · filed 2022-11-08 | $428.19K derived: sum of 2 quarters · filed 2022-11-08 | $450.23K derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $28.37K 10-Q · filed 2022-11-08 | $50.41K derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $22.04K 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $92.87K 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $29.27K 10-Q · filed 2021-11-04 | $58.55K derived: sum of 2 quarters · filed 2021-11-04 | $80.60K derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $29.29K 10-Q · filed 2021-11-04 | $51.33K derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $22.05K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |